These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 1616246)

  • 21. [Report of experiences with the oral cephalosporin-derivative cephaclor in respiratory tract infections].
    Spath P
    Wien Med Wochenschr; 1983 Jan; 133(1):27-30. PubMed ID: 6837048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antibiotic resistance in respiratory tract infections: what can we do?].
    Flückiger U
    Praxis (Bern 1994); 2001 May; 90(21):931-4. PubMed ID: 11441707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind study comparing cefaclor and amoxycillin in the treatment of respiratory tract infections in general practice.
    Brodie NH; McGhie RL; O'Hara H; O'Hara J; Rahman MK; Vallé-Jones JC
    Pharmatherapeutica; 1980; 2(7):494-8. PubMed ID: 7010383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibacterial activity of carbapenems against clinically isolated respiratory bacterial pathogens in Japan between 2003 and 2004.
    Watanabe A; Tokue Y; Kikuchi T; Gomi K; Aoki S; Satoh T; Fujimura S
    Int J Antimicrob Agents; 2005 Nov; 26(5):420-3. PubMed ID: 16216468
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug resistant Haemophilus influenzae from respiratory tract infection in a tertiary care hospital in north India.
    Nag VL; Ayyagari A; Venkatesh V; Ghar M; Yadav V; Prasad KN
    Indian J Chest Dis Allied Sci; 2001; 43(1):13-7. PubMed ID: 11370501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized clinical trial comparing the safety and efficacy of cefonicid and cefamandole in the treatment of patients with respiratory tract infections caused by susceptible pathogens.
    Azanza JR; Honorato J; Rubio A; Cuena R
    Chemioterapia; 1987 Jun; 6(2 Suppl):449-51. PubMed ID: 3334597
    [No Abstract]   [Full Text] [Related]  

  • 27. [Rondomycin in the therapy of chronic diseases of the respiratory tract (report of clinical experiences)].
    Jahn O
    Wien Med Wochenschr; 1968 Jun; 118(22):503-10. PubMed ID: 4886000
    [No Abstract]   [Full Text] [Related]  

  • 28. [Antibiotic resistance of pathogenic bacteria related to respiratory infections in children from Shanghai].
    Che DT; Lu M; Zhang H; Li WH; Lu Q
    Zhongguo Dang Dai Er Ke Za Zhi; 2006 Aug; 8(4):338-40. PubMed ID: 16923372
    [No Abstract]   [Full Text] [Related]  

  • 29. [Comparison of in vitro activity of 4 oral beta-lactams on microorganisms responsible for broncho-pulmonary infections in children].
    Lambert-Zechovsky N; Mariani-Kurkdjian P; Bingen E; Lemer G; Sauzeau C
    Pathol Biol (Paris); 1988 Jun; 36(5 Pt 2):738-41. PubMed ID: 3054759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Bacteriologic examinations of sputum in non-tuberculous diseases of the respiratory tract].
    Bartmann K
    Dtsch Med Wochenschr; 1967 Sep; 92(37):1680-1. PubMed ID: 4861445
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of cefaclor.
    Derry JE
    Am J Hosp Pharm; 1981 Jan; 38(1):54-8. PubMed ID: 7011003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Reevaluation of current antimicrobials. Cefaclor].
    Sunakawa K; Shiba K
    Jpn J Antibiot; 1994 Jul; 47(7):853-60. PubMed ID: 7933517
    [No Abstract]   [Full Text] [Related]  

  • 33. Roxithromycin vs cefaclor.
    Hughes T; Scott WG; Scott HM
    Pharmacoeconomics; 1993 Nov; 4(5):396-8. PubMed ID: 10146876
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost effectiveness of roxithromycin versus cefaclor in Australia.
    Scott WG; Cooper BC; Scott HM; Tilyard MW; Dovey SM
    Pharmacoeconomics; 1995 Jan; 7(1):93-4. PubMed ID: 10155297
    [No Abstract]   [Full Text] [Related]  

  • 35. Why now? Use of tetracycline in young children.
    Yeager AS
    JAMA; 1977 May; 237(19):2101. PubMed ID: 576894
    [No Abstract]   [Full Text] [Related]  

  • 36. [Importance of an antibiogram in the treatment of upper respiratory tract infections in children].
    Danielewicz J; Korycki Z
    Otolaryngol Pol; 1968; 22(1):33-5. PubMed ID: 5647386
    [No Abstract]   [Full Text] [Related]  

  • 37. Maximizing outcomes in respiratory tract infections in the age of resistance.
    Nicolau DP
    Pharmacotherapy; 2002 Jan; 22(1 Pt 2):1S; discussion 30S-32S. PubMed ID: 11791626
    [No Abstract]   [Full Text] [Related]  

  • 38. [Extraintestinal incidence of the dysentery pathogen].
    Grossmann M; Nedvĕdová M
    Cesk Pediatr; 1975 May; 30(5):211-3. PubMed ID: 1164768
    [No Abstract]   [Full Text] [Related]  

  • 39. Advances in antimicrobial therapy: extended release cefaclor AF.
    Brumfitt W
    Postgrad Med J; 1992; 68 Suppl 3():S1-2. PubMed ID: 1287611
    [No Abstract]   [Full Text] [Related]  

  • 40. What's new with upper respiratory infections?
    Shulman ST
    Pediatr Ann; 2010 Jan; 39(1):3-4. PubMed ID: 20151616
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.